search
Back to results

Focal Cerebral Arteriopathy Steroid Trial (FOCAS)

Primary Purpose

Focal Cerebral Arteriopathy, Pediatric Stroke, Arteriopathy

Status
Not yet recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
methylprednisolone, prednisolone, prednisone
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Focal Cerebral Arteriopathy focused on measuring FCA, Focal cerebral arteriopathy, Pediatric stroke, Arterial ischemic stroke

Eligibility Criteria

1 Year - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 1 year through 18 years at stroke/TIA ictus (ineligible as of 19th birthday). Acute arterial ischemic stroke (AIS) or transient ischemic attack (TIA) in prior 4 days (96 hours). AIS definition: neurological deficit with acute onset (including seizures) and acute infarct(s) corresponding to arterial territory(ies) on brain imaging. TIA definition: neurological deficit with acute onset (not including seizures) consistent with ischemia of an arterial territory(ies) but without acute infarction on brain imaging. Imaging inclusion criteria: a. Baseline imaging findings consistent with FCA: i. unilateral focal irregularity, banding, stenosis, wall thickening/enhancement, or occlusion of the distal internal carotid artery (ICA) and/or its proximal branches (A1, M1, posterior communicating artery, proximal PCA), OR ii. unilateral infarction in the territory of the lenticulostriate arteries with normal MRA. b. Ability to return at 1-month (±7 days) post-stroke for an MRI/MRA (non-contrast) on a scanner of the same magnet strength as baseline MRI/MRA.* Consent to study procedures. A repeat baseline MRI/MRA can be performed as a research scan within 24 hours of enrollment if needed to meet this requirement. Exclusion Criteria: Prior stroke. Another identified cause of stroke/TIA, other than FCA. (Intracranial dissection is considered a subtype of FCA and will be included if the patient is not predisposed to dissection for the reasons listed below.) Presence of childhood stroke risk factors (known to be present at the time of enrollment): Risk factors for arterial dissection: connective tissue disorder (e.g., Ehlers-Danlos type IV, Marfan syndrome, osteogenesis imperfect); severe head or neck trauma in the two weeks preceding AIS/TIA (defined as skull or cervical fracture, or an ICU admission for trauma). Risk factors for moyamoya: genetic disorder or syndrome that predisposes to moyamoya (e.g., trisomy 21, neurofibromatosis type 1, tuberous sclerosis, sickle cell anemia, MOPD type II, PHACE syndrome); prior cranial radiation therapy. Risk factors for secondary vasculitis or vasospasm: acute meningitis, systemic lupus erythematosus or other autoimmune disorder that can cause vasculitis, recent cocaine/amphetamine use (prior 7 days), recent subarachnoid hemorrhage (prior 14 days). Risk factors for cardioembolism: complex congenital heart disease; recent cardiac surgery or catheterization (prior week); endocarditis or other cardiac valve disease with vegetations; right-to-left cardiac shunting lesion with deep vein thrombosis (DVT) or a known thrombophilia. Imaging exclusion criteria: Baseline parenchymal imaging demonstrating remote or bilateral infarcts Vascular imaging demonstrating bilateral arteriopathy or moyamoya collaterals Contraindication to corticosteroid therapy (e.g., baseline immunosuppression, significant infection, etc.) as determined by the treating physicians. Current or recent (within prior week) treatment with corticosteroids. Pregnant, post-partum (within 6 months of childbirth), or nursing.

Sites / Locations

  • University of California San Francisco

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Arm A

Arm B

Arm Description

Treat all children with suspected FCA with corticosteroids as soon as the diagnosis is made.

Treat only the subset of children that develop evidence of FCA disease progression.

Outcomes

Primary Outcome Measures

Change in Focal Cerebral Arteriopathy Severity Score (FCASS)
Change in FCASS from baseline to 1 month (1-month delta FCASS) measured centrally on MRA studies (performed on scanners with the same magnet strength). The FCASS is a novel ordinal scale designed and validated for the FOCAS and PASTA trials (Fullerton HJ, Stroke, 2018; Slalova, Eur J Paediatr Neurol, 2020) . The FCASS sums the severity of involvement of each of 5 different arterial segments that can be involved in FCA: (1) supraclinoid ICA (very common), (2) M1 segment of the MCA (very common), (3) M2 branches, (4) A1 segment of the ACA, (5) A2 branches of the ACA. The involvement of the ICA, M1, and A1 are scored on a scale of 0 to 4: 0=no involvement, 1=irregularity or banding without stenosis, 2=less than 50% stenosis, 3= 50% stenosis or greater), 4=complete occlusion. The M2 and A2 are scored: 0=no involvement, 1=irregularity, 3=stenosis, 4=complete occlusion (no option for 2).

Secondary Outcome Measures

FCASS at 1 month (required)
In addition to analyzing the change in FCASS from baseline to 1 month, we will analyze the absolute FCASS at 1 month. VIPS data suggest that the 1-month measurement should best approximate the maximum FCASS.
FCASS at 1 month at 12 months (when imaging is available)
We will also analyze the FCASS at 12 months, which should approximate the final FCASS value (after recovery).
Relative infarct volume at 1 month (required)
Study neuroradiologists, blinded to the treatment arm and imaging date, will estimate relative infarct volume at 1 month. They will first estimate the absolute infarct volume using ABC/2.39 They will delineate the infarct contour and the brain contour on FLAIR images and, taking into account FLAIR slice thickness, calculate the absolute infarct volume and total brain volume. To account for smaller head sizes in young children, they will then calculate the relative infarct volume as a percent of total brain volume.
Relative infarct volume at 12 months (when imaging is available)
Study neuroradiologists, blinded to the treatment arm and imaging date, will estimate relative infarct volume at 1 month. They will first estimate the absolute infarct volume using ABC/2.39 They will delineate the infarct contour and the brain contour on FLAIR images and, taking into account FLAIR slice thickness, calculate the absolute infarct volume and total brain volume. To account for smaller head sizes in young children, they will then calculate the relative infarct volume as a percent of total brain volume. They will use similar methodology to also estimate the final infarct volume at 12 months.
Pediatric Stroke Outcome Measure (PSOM) at 6 months
The PSOM can be measured via the Pediatric Stroke Recurrence and Recovery Questionnaire (RRQ) if only telephone follow-up is feasible. The PSOM scale ranges from 0 to 10, but 6- and 12-month measurements typically cluster between 0 and 3, with any value ≥1 considered a "poor outcome." The median 1-year PSOM in our FCA cohort (N=39 with 1-year outcomes) was 1 (IQR 0, 1.5; range 0, 4.5). 2 In VIPS, higher maximum FCASS correlated with higher PSOM scores, indicating poorer outcomes (p=0.037).
Pediatric Stroke Outcome Measure (PSOM) at 12 months (when feasible)
The PSOM can be measured via the Pediatric Stroke Recurrence and Recovery Questionnaire (RRQ) if only telephone follow-up is feasible. The PSOM scale ranges from 0 to 10, but 6- and 12-month measurements typically cluster between 0 and 3, with any value ≥1 considered a "poor outcome." The median 1-year PSOM in our FCA cohort (N=39 with 1-year outcomes) was 1 (IQR 0, 1.5; range 0, 4.5). 2 In VIPS, higher maximum FCASS correlated with higher PSOM scores, indicating poorer outcomes (p=0.037).

Full Information

First Posted
September 8, 2023
Last Updated
September 8, 2023
Sponsor
University of California, San Francisco
Collaborators
University of Cincinnati, Medical University of South Carolina, M.D. Anderson Cancer Center, University of Colorado, Denver, University of Iowa, National Institute of Neurological Disorders and Stroke (NINDS), American Heart Association
search

1. Study Identification

Unique Protocol Identification Number
NCT06040255
Brief Title
Focal Cerebral Arteriopathy Steroid Trial
Acronym
FOCAS
Official Title
Focal Cerebral Arteriopathy Steroid Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 1, 2023 (Anticipated)
Primary Completion Date
July 31, 2029 (Anticipated)
Study Completion Date
January 31, 2030 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
University of Cincinnati, Medical University of South Carolina, M.D. Anderson Cancer Center, University of Colorado, Denver, University of Iowa, National Institute of Neurological Disorders and Stroke (NINDS), American Heart Association

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This comparative effectiveness trial (CET) in children with suspected focal cerebral arteriopathy (FCA) presenting with arterial ischemic stroke (AIS) or transient ischemic attack (TIA) will compare the use of early corticosteroid treatment (Arm A) versus delayed/no corticosteroid treatment (Arm B). Delayed corticosteroid treatment is given only for those demonstrating disease progression and is initiated as soon as the progression is detected (at any time after randomization). All participants will also receive standard of care therapy (aspirin and supportive care). Sites will randomize participants 1:1 to Arm A or B. Participants will be enrolled and randomized as soon as possible after their stroke/TIA up until 96 hours following the initial stroke/TIA event.
Detailed Description
FCA is an acute, monophasic, presumed inflammatory disease that causes unilateral stenosis of the intracranial anterior circulation. In the medical literature, it has also been called transient cerebral arteriopathy (TCA) and post-varicella arteriopathy when it occurs after chicken pox. Although rare (1 to 3 cases seen per year at a typical academic children's hospital in the US), it is one of the most common causes of arterial ischemic stroke in a previously healthy child. Pediatric stroke investigators identified an FCA treatment trial as the #1 priority of the field (Steinlin M, Dev Med Child Neurol 2017) because of its aggressive natural history: it often progresses dramatically over days to weeks with recurrent or expanding infarcts. A 2017 European retrospective cohort study suggested that corticosteroid treatment may improve outcomes for FCA (Steinlin M, Stroke 2017). Europeans have begun the PASTA (Paediatric Arteriopathy STeroid Aspirin) trial (PI Steinlin): a "gold-standard" RCT to test the efficacy of corticosteroids for FCA. A 2018 survey of pediatric stroke investigators (participating in the NIH-funded Vascular effects of Infection in Pediatric Stroke, VIPS II, cohort study) revealed discomfort with randomization to "no steroids" as the majority now treat FCA with corticosteroids. However, despite attitudes favoring their use, corticosteroids were given to only 36% of 55 children with suspected FCA in the VIPS II cohort and (when given) were started a median of 3 days post-stroke (IQR 1.5, 6) (unpublished preliminary data). This incongruity reflects diagnostic uncertainty at stroke baseline: the characteristic arteriopathy evolution is needed for definitive diagnosis of FCA, and ≈1 in 5 children with suspected FCA at baseline have an alternate diagnosis. Hence, the pressing clinical question is: Should we treat all children with suspected FCA immediately or wait and treat only the subset that demonstrate disease progression? Early treatment has the potential advantage of preventing FCA progression, but the disadvantage of over treatment of those with alternate diagnoses. With a comparative effectiveness approach, the FOCAS trial will compare these two treatment approaches. FOCAS will also collect the steroid treatment safety data needed to guide clinical decisions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Focal Cerebral Arteriopathy, Pediatric Stroke, Arteriopathy, Arterial Ischemic Stroke
Keywords
FCA, Focal cerebral arteriopathy, Pediatric stroke, Arterial ischemic stroke

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Because corticosteroids cause significant behavioral effects in children, the local study investigators cannot be effectively blinded to the treatment; however, one of the study biostatisticians and all personnel reviewing neuroimaging as a part of the neuroimaging core will be blinded to Study Arm assignment.
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm A
Arm Type
Active Comparator
Arm Description
Treat all children with suspected FCA with corticosteroids as soon as the diagnosis is made.
Arm Title
Arm B
Arm Type
Active Comparator
Arm Description
Treat only the subset of children that develop evidence of FCA disease progression.
Intervention Type
Drug
Intervention Name(s)
methylprednisolone, prednisolone, prednisone
Intervention Description
Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.
Primary Outcome Measure Information:
Title
Change in Focal Cerebral Arteriopathy Severity Score (FCASS)
Description
Change in FCASS from baseline to 1 month (1-month delta FCASS) measured centrally on MRA studies (performed on scanners with the same magnet strength). The FCASS is a novel ordinal scale designed and validated for the FOCAS and PASTA trials (Fullerton HJ, Stroke, 2018; Slalova, Eur J Paediatr Neurol, 2020) . The FCASS sums the severity of involvement of each of 5 different arterial segments that can be involved in FCA: (1) supraclinoid ICA (very common), (2) M1 segment of the MCA (very common), (3) M2 branches, (4) A1 segment of the ACA, (5) A2 branches of the ACA. The involvement of the ICA, M1, and A1 are scored on a scale of 0 to 4: 0=no involvement, 1=irregularity or banding without stenosis, 2=less than 50% stenosis, 3= 50% stenosis or greater), 4=complete occlusion. The M2 and A2 are scored: 0=no involvement, 1=irregularity, 3=stenosis, 4=complete occlusion (no option for 2).
Time Frame
Baseline to one month
Secondary Outcome Measure Information:
Title
FCASS at 1 month (required)
Description
In addition to analyzing the change in FCASS from baseline to 1 month, we will analyze the absolute FCASS at 1 month. VIPS data suggest that the 1-month measurement should best approximate the maximum FCASS.
Time Frame
Baseline to 1 month
Title
FCASS at 1 month at 12 months (when imaging is available)
Description
We will also analyze the FCASS at 12 months, which should approximate the final FCASS value (after recovery).
Time Frame
Baseline to 12 months
Title
Relative infarct volume at 1 month (required)
Description
Study neuroradiologists, blinded to the treatment arm and imaging date, will estimate relative infarct volume at 1 month. They will first estimate the absolute infarct volume using ABC/2.39 They will delineate the infarct contour and the brain contour on FLAIR images and, taking into account FLAIR slice thickness, calculate the absolute infarct volume and total brain volume. To account for smaller head sizes in young children, they will then calculate the relative infarct volume as a percent of total brain volume.
Time Frame
1 month after baseline
Title
Relative infarct volume at 12 months (when imaging is available)
Description
Study neuroradiologists, blinded to the treatment arm and imaging date, will estimate relative infarct volume at 1 month. They will first estimate the absolute infarct volume using ABC/2.39 They will delineate the infarct contour and the brain contour on FLAIR images and, taking into account FLAIR slice thickness, calculate the absolute infarct volume and total brain volume. To account for smaller head sizes in young children, they will then calculate the relative infarct volume as a percent of total brain volume. They will use similar methodology to also estimate the final infarct volume at 12 months.
Time Frame
12 months after baseline
Title
Pediatric Stroke Outcome Measure (PSOM) at 6 months
Description
The PSOM can be measured via the Pediatric Stroke Recurrence and Recovery Questionnaire (RRQ) if only telephone follow-up is feasible. The PSOM scale ranges from 0 to 10, but 6- and 12-month measurements typically cluster between 0 and 3, with any value ≥1 considered a "poor outcome." The median 1-year PSOM in our FCA cohort (N=39 with 1-year outcomes) was 1 (IQR 0, 1.5; range 0, 4.5). 2 In VIPS, higher maximum FCASS correlated with higher PSOM scores, indicating poorer outcomes (p=0.037).
Time Frame
6 months after baseline
Title
Pediatric Stroke Outcome Measure (PSOM) at 12 months (when feasible)
Description
The PSOM can be measured via the Pediatric Stroke Recurrence and Recovery Questionnaire (RRQ) if only telephone follow-up is feasible. The PSOM scale ranges from 0 to 10, but 6- and 12-month measurements typically cluster between 0 and 3, with any value ≥1 considered a "poor outcome." The median 1-year PSOM in our FCA cohort (N=39 with 1-year outcomes) was 1 (IQR 0, 1.5; range 0, 4.5). 2 In VIPS, higher maximum FCASS correlated with higher PSOM scores, indicating poorer outcomes (p=0.037).
Time Frame
12 months after baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 1 year through 18 years at stroke/TIA ictus (ineligible as of 19th birthday). Acute arterial ischemic stroke (AIS) or transient ischemic attack (TIA) in prior 4 days (96 hours). AIS definition: neurological deficit with acute onset (including seizures) and acute infarct(s) corresponding to arterial territory(ies) on brain imaging. TIA definition: neurological deficit with acute onset (not including seizures) consistent with ischemia of an arterial territory(ies) but without acute infarction on brain imaging. Imaging inclusion criteria: a. Baseline imaging findings consistent with FCA: i. unilateral focal irregularity, banding, stenosis, wall thickening/enhancement, or occlusion of the distal internal carotid artery (ICA) and/or its proximal branches (A1, M1, posterior communicating artery, proximal PCA), OR ii. unilateral infarction in the territory of the lenticulostriate arteries with normal MRA. b. Ability to return at 1-month (±7 days) post-stroke for an MRI/MRA (non-contrast) on a scanner of the same magnet strength as baseline MRI/MRA.* Consent to study procedures. A repeat baseline MRI/MRA can be performed as a research scan within 24 hours of enrollment if needed to meet this requirement. Exclusion Criteria: Prior stroke. Another identified cause of stroke/TIA, other than FCA. (Intracranial dissection is considered a subtype of FCA and will be included if the patient is not predisposed to dissection for the reasons listed below.) Presence of childhood stroke risk factors (known to be present at the time of enrollment): Risk factors for arterial dissection: connective tissue disorder (e.g., Ehlers-Danlos type IV, Marfan syndrome, osteogenesis imperfect); severe head or neck trauma in the two weeks preceding AIS/TIA (defined as skull or cervical fracture, or an ICU admission for trauma). Risk factors for moyamoya: genetic disorder or syndrome that predisposes to moyamoya (e.g., trisomy 21, neurofibromatosis type 1, tuberous sclerosis, sickle cell anemia, MOPD type II, PHACE syndrome); prior cranial radiation therapy. Risk factors for secondary vasculitis or vasospasm: acute meningitis, systemic lupus erythematosus or other autoimmune disorder that can cause vasculitis, recent cocaine/amphetamine use (prior 7 days), recent subarachnoid hemorrhage (prior 14 days). Risk factors for cardioembolism: complex congenital heart disease; recent cardiac surgery or catheterization (prior week); endocarditis or other cardiac valve disease with vegetations; right-to-left cardiac shunting lesion with deep vein thrombosis (DVT) or a known thrombophilia. Imaging exclusion criteria: Baseline parenchymal imaging demonstrating remote or bilateral infarcts Vascular imaging demonstrating bilateral arteriopathy or moyamoya collaterals Contraindication to corticosteroid therapy (e.g., baseline immunosuppression, significant infection, etc.) as determined by the treating physicians. Current or recent (within prior week) treatment with corticosteroids. Pregnant, post-partum (within 6 months of childbirth), or nursing.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kathleen M Colao, MPH
Phone
415 353 9465
Email
Kathleen.Colao@ucsf.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Maria A Kuchherzki, BA
Phone
415 502 7298
Email
Maria.Kuchherzki@ucsf.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Heather J Fullerton, MD, MAS
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94158
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Heather J. Fullerton, MD,MAS
Phone
415-502-7298
Email
Heather.Fullerton@ucsf.edu

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28982784
Citation
Wintermark M, Hills NK, DeVeber GA, Barkovich AJ, Bernard TJ, Friedman NR, Mackay MT, Kirton A, Zhu G, Leiva-Salinas C, Hou Q, Fullerton HJ; VIPS Investigators. Clinical and Imaging Characteristics of Arteriopathy Subtypes in Children with Arterial Ischemic Stroke: Results of the VIPS Study. AJNR Am J Neuroradiol. 2017 Nov;38(11):2172-2179. doi: 10.3174/ajnr.A5376. Epub 2017 Oct 5.
Results Reference
background
PubMed Identifier
30355212
Citation
Fullerton HJ, Stence N, Hills NK, Jiang B, Amlie-Lefond C, Bernard TJ, Friedman NR, Ichord R, Mackay MT, Rafay MF, Chabrier S, Steinlin M, Elkind MSV, deVeber GA, Wintermark M; VIPS Investigators. Focal Cerebral Arteriopathy of Childhood: Novel Severity Score and Natural History. Stroke. 2018 Nov;49(11):2590-2596. doi: 10.1161/STROKEAHA.118.021556.
Results Reference
background
PubMed Identifier
26813104
Citation
Elkind MS, Hills NK, Glaser CA, Lo WD, Amlie-Lefond C, Dlamini N, Kneen R, Hod EA, Wintermark M, deVeber GA, Fullerton HJ; VIPS Investigators*. Herpesvirus Infections and Childhood Arterial Ischemic Stroke: Results of the VIPS Study. Circulation. 2016 Feb 23;133(8):732-41. doi: 10.1161/CIRCULATIONAHA.115.018595. Epub 2016 Jan 26.
Results Reference
background
PubMed Identifier
28733481
Citation
Steinlin M, Bigi S, Stojanovski B, Gajera J, Regenyi M, El-Koussy M, Mackay MT; Swiss NeuroPediatric Stroke Registry. Focal Cerebral Arteriopathy: Do Steroids Improve Outcome? Stroke. 2017 Sep;48(9):2375-2382. doi: 10.1161/STROKEAHA.117.016818. Epub 2017 Jul 21.
Results Reference
background
PubMed Identifier
28121022
Citation
Steinlin M, O'callaghan F, Mackay MT. Planning interventional trials in childhood arterial ischaemic stroke using a Delphi consensus process. Dev Med Child Neurol. 2017 Jul;59(7):713-718. doi: 10.1111/dmcn.13393. Epub 2017 Jan 25.
Results Reference
background
PubMed Identifier
26423434
Citation
Fullerton HJ, Hills NK, Elkind MS, Dowling MM, Wintermark M, Glaser CA, Tan M, Rivkin MJ, Titomanlio L, Barkovich AJ, deVeber GA; VIPS Investigators. Infection, vaccination, and childhood arterial ischemic stroke: Results of the VIPS study. Neurology. 2015 Oct 27;85(17):1459-66. doi: 10.1212/WNL.0000000000002065. Epub 2015 Sep 30.
Results Reference
background
PubMed Identifier
15728288
Citation
Lanthier S, Armstrong D, Domi T, deVeber G. Post-varicella arteriopathy of childhood: natural history of vascular stenosis. Neurology. 2005 Feb 22;64(4):660-3. doi: 10.1212/01.WNL.0000151851.66154.27.
Results Reference
background
PubMed Identifier
9477245
Citation
Chabrier S, Rodesch G, Lasjaunias P, Tardieu M, Landrieu P, Sebire G. Transient cerebral arteriopathy: a disorder recognized by serial angiograms in children with stroke. J Child Neurol. 1998 Jan;13(1):27-32. doi: 10.1177/088307389801300105.
Results Reference
background
PubMed Identifier
19039009
Citation
Braun KP, Bulder MM, Chabrier S, Kirkham FJ, Uiterwaal CS, Tardieu M, Sebire G. The course and outcome of unilateral intracranial arteriopathy in 79 children with ischaemic stroke. Brain. 2009 Feb;132(Pt 2):544-57. doi: 10.1093/brain/awn313. Epub 2008 Nov 27.
Results Reference
background
PubMed Identifier
32826156
Citation
Slavova N, Fullerton HJ, Hills NK, Breiding PS, Mackay MT, Steinlin M. Validation of the focal cerebral arteriopathy severity score (FCASS) in a Swiss cohort: Correlation with infarct volume and outcome. Eur J Paediatr Neurol. 2020 Sep;28:58-63. doi: 10.1016/j.ejpn.2020.07.015. Epub 2020 Aug 4.
Results Reference
background
PubMed Identifier
22895580
Citation
Lo WD, Ichord RN, Dowling MM, Rafay M, Templeton J, Halperin A, Smith SE, Licht DJ, Moharir M, Askalan R, Deveber G; International Pediatric Stroke Study (IPSS) Investigators. The Pediatric Stroke Recurrence and Recovery Questionnaire: validation in a prospective cohort. Neurology. 2012 Aug 28;79(9):864-70. doi: 10.1212/WNL.0b013e318266fc9a. Epub 2012 Aug 15.
Results Reference
background
PubMed Identifier
22160380
Citation
Schechter T, Kirton A, Laughlin S, Pontigon AM, Finkelstein Y, MacGregor D, Chan A, deVeber G, Brandao LR. Safety of anticoagulants in children with arterial ischemic stroke. Blood. 2012 Jan 26;119(4):949-56. doi: 10.1182/blood-2011-06-361535. Epub 2011 Dec 7.
Results Reference
background

Learn more about this trial

Focal Cerebral Arteriopathy Steroid Trial

We'll reach out to this number within 24 hrs